What Happened?
San Diego, CA-based Dauntless Pahrmaceuicals Appointed Joel Martin as Chief Executive Officer
About the Company
Dauntless Pharmaceuticals, Inc is a San Diego, CA-based biopharmaceutical company. The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share interest in all company assets. In contrast, Dauntless uses a one-asset, one-company model.
About the Person
Joel F. Martin, PhD, is our President and Chief Executive Officer (CEO), a co-founder, and serves on our Board of Directors. From 2013 to January 2015, Dr. Martin was the President and CEO of Cebix Incorporated, a company that advanced a diabetes drug rapidly through a large, international Phase 2b trial. From 2008 to 2010, Dr. Martin was President and CEO of Altair Therapeutics, a Phase 2 asthma company that was acquired in 2010. Dr. Martin has extensive venture capital experience and maintains strong connections throughout the venture industry. He was a partner at Forward Ventures from 2001 through 2008, where he led successful investments in neuroscience and cancer companies such as Hypnion, Predix, and Cellective Therapeutics. He was previously an executive-in-residence and associate at Institutional Venture Partners and Avalon Ventures, respectively. Dr. Martin is a skilled serial entrepreneur. He was the co-founder and CEO of Quantum Dot Corporation (acquired by Invitrogen), a company that pioneered quantum-confined luminescent nanocrystals, arguably the first commercial nanotechnology product. Prior to that, he was the co-founder and CEO of Argonaut Technologies, a publically traded chemistry automation and solid-phase reagents company, which was acquired by Biotage AB. At Argonaut, he pioneered a new business model, where a consortium of pharmaceutical companies financed product development with non-dilutive capital. Dr. Martin began his career as assistant professor of radiology at University of California, San Diego (UCSD) where he pioneered novel digital image processing techniques and invented the first medical device for MRI imaging of the prostate. Dr. Martin earned his Ph.D. in physical chemistry from UCSD and holds MBA and B.S. Chem. Honors degrees from the University of Michigan, Ann Arbor. He did postdoctoral research combining MRI imaging with NMR spectroscopy at IBM. He is currently a member of the advisory boards of the Life Sciences Institute at the University of Michigan and the Rady School of Business at UCSD.
Info Source
Press Release
Short Profile